Trial on Radical Upfront Surgery in Advanced Ovarian Cancer (NCT02828618)
🩺 Plain-English Summary (8th-Grade Level)
This study consists of three parts, whereas Part 1 and Part 2 are performed in Germany only, and Part 3 is a multinational trial. All patients with suspicion of advanced ovarian cancer are detected in the participating study centers in a pre-screening. The study centers will register all patients with suspected ovarian cancer in a screening log. After the patients have given informed consent, they can be enrolled in different parts of the study. TRUST-Trial: This part compares two strategies in the therapy of advanced ovarian cancer. En detail, this part of the trial will evaluate if one of two strategies of timing surgery within the therapeutic procedures may show any significant advances in terms of overall survival over the other.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (16 items) and avoid the listed exclusions (11 items).
Location: Memorial Sloan Kettering Cancer Center — New York, New York
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Non epithelial ovarian malignancies and borderline tumors
- Secondary invasive neoplasms in the last 5 years (except synchronal endometrial carcinoma FIGO IA G1/2, non melanoma skin cancer, breast cancer T1 N0 M0 G1/2) or with any signs of relapse or activity.
- Recurrent ovarian cancer
- Prior chemotherapy for ovarian cancer or abdominal/pelvic radiotherapy
- Unresectable parenchymal lung metastasis, liver metastasis or bulky lymph-nodes in the mediastinum in CT chest and abdomen/pelvis
- Clinical relevant dysfunctions of blood clotting (including drug induced)
- Any significant medical reasons, age or performance status that will not allow to perform the study procedures (estimation of investigator)
- Pregnancy
- Dementia or significantly altered mental status that would prohibit the understanding and giving of informed consent
- Any reasons interfering with regular follow-up
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (20 Sites)
- Memorial Sloan Kettering Cancer Center — New York, New York
- Medical University of Vienna — Vienna,
- University Hospital, Rigshospitalet — Copenhagen,
- Institut Bergonié — Bordeaux,
- Hôpital Européen Georges Pompidou (HEGP) — Paris,
- Institute Gustave Roussy — Villejuif,
- Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Klinik für Gynäkologie — Berlin,
- Universitätsklinikum Carl Gustav Carus Dresden, Klinik & Poliklinik f. Frauenheilkunde & Geburtshilfe — Dresden,
- Kaiserswerther Diakonie; Florence-Nightingale-Hospital — Düsseldorf,
- Kliniken Essen-Mitte, Evang. Huyssens-Stiftung, Klinik für Gynäkologie und gyn. Onkologie — Essen,
- Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie — Hamburg,
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München — München,
- Klinikum rechts der Isar, Frauen- und Poliklinik — München,
- Universitätsklinikum Tübingen — Tübingen,
- European Institute of Oncology; Gynecologic Cancer Surgery — Milan,
- Fondazione IRCCS Istituto Nazionale Tumori - Milan — Milan,
- Istituto Nazionale per lo Studio e la Cura dei Tumori di Napoli — Naples,
- Skane University Hospital — Lund,
- Karolinska University Hospital — Solna,
- Imperial College London, Hammersmith Hospital, Surgery&Cancer — London,
📞 Contact the Study Coordinator
Phone: (800) 525-2225
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ovarian Cancer
- Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy — New York, New York
- Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer — Pittsburgh, Pennsylvania
- Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer — Houston, Texas
- Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy — Miami, Florida
- Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors — Duarte, California
Explore by condition: All Ovarian Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.